{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T23:58:43Z","timestamp":1793663923281,"version":"4.5.1"},"reference-count":80,"publisher":"Journal of Neurosurgery Publishing Group (JNSPG)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,1]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>This study was conducted to explore the role of serum amyloid A2 (SAA2) protein in the phenotype changes of vascular smooth muscle cells (VSMCs) in moyamoya disease (MMD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>Between January 2020 and August 2022, individuals with diagnosed MMD were identified through a combination of their neuroradiological assessments and medical history. Control participants consisted of healthy adult volunteers who did not have MMD or any preexisting diseases. Data-independent acquisition (DIA) mass spectrometry was used to identify differentially expressed proteins in the serum of 40 MMD patients and 20 healthy controls (HCs), a discovery cohort of 60 patients. These proteins were validated with an enzyme-linked immunosorbent assay using the serum of another 15 MMD patients and 15 HCs plus 5 randomly selected samples each from the MMD patients and the HCs in the discovery cohort, bringing the validation cohort to 20 MMD patients and 20 HCs. In vitro experiments, including western blotting, flow cytometry, scratch tests, and cell proliferation assays, were performed to explore the effects and mechanisms of these proteins on smooth muscle cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      Proteomic analysis showed significant upregulation of SAA2 protein in the MMD serum compared to that in the HC serum (log\n                      <jats:sub>2<\/jats:sub>\n                      FC [MMD\/HC] = 2.797, p &lt; 0.05). SAA2 increased the proportion of VSMCs in the S phase and promoted their proliferation, migration, and contractile-to-synthetic phenotypic switching. Aspirin reversed SAA2-induced changes in VSMCs. Mechanistic studies revealed that the ERK1\/2 and AKT signaling pathways play a major role in SAA2-induced changes in VSMCs.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>This study revealed that SAA2 is upregulated in the serum of MMD patients. The overexpression of SAA2 in MMD patients and in subsequent in vitro experiments suggests that the SAA2 protein promotes phenotypic changes in VSMCs and is related to cerebrovascular intimal thickening in MMD, with diagnostic and therapeutic ramifications.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3171\/2024.11.jns241804","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T21:54:24Z","timestamp":1744408464000},"page":"530-542","source":"Crossref","is-referenced-by-count":7,"title":["Serum amyloid A2\u2013induced phenotypic switching of vascular smooth muscle cells in moyamoya disease"],"prefix":"10.3171","volume":"143","author":[{"given":"Shihao","family":"He","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing;"},{"name":"Department of Neurosurgery, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junze","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing;"},{"name":"China National Clinical Research Center for Neurological Diseases, Beijing;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyu","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing;"},{"name":"China National Clinical Research Center for Neurological Diseases, Beijing;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanru","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing;"},{"name":"China National Clinical Research Center for Neurological Diseases, Beijing;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xilong","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing;"},{"name":"China National Clinical Research Center for Neurological Diseases, Beijing;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongchuan","family":"Niu","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Peking University International Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanli","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing;"},{"name":"Department of Neurosurgery, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing;"},{"name":"China National Clinical Research Center for Neurological Diseases, Beijing;"},{"name":"Department of Neurosurgery, Peking University International Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xun","family":"Ye","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing;"},{"name":"China National Clinical Research Center for Neurological Diseases, Beijing;"},{"name":"Department of Neurosurgery, Peking University International Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1754","reference":[{"issue":"11","key":"b1","series-title":"Lancet Neurol","first-page":"1056","article-title":"Moyamoya disease: current concepts and future perspectives","volume":"7","author":"Kuroda S","year":"2008","unstructured":"Kuroda S, Houkin K. Moyamoya disease: current concepts and future perspectives. Lancet Neurol. 2008; 7(11):1056\u20131066."},{"issue":"7","key":"b2","series-title":"Stroke","first-page":"e364","article-title":"2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: a guideline from the American Heart Association\/American Stroke Association","volume":"52","author":"Kleindorfer DO","year":"2021","unstructured":"Kleindorfer DO, Towfighi A, Chaturvedi S,  2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: a guideline from the American Heart Association\/American Stroke Association. Stroke. 2021; 52(7):e364\u2013e467."},{"key":"b3","series-title":"Front Pharmacol","first-page":"841174","article-title":"Effects of aspirin therapy on bypass efficacy and survival of patients receiving direct cerebral revascularization","volume":"13","author":"Xiang Y","year":"2022","unstructured":"Xiang Y, Zhang P, Zhao P,  Effects of aspirin therapy on bypass efficacy and survival of patients receiving direct cerebral revascularization. Front Pharmacol. 2022; 13:841174."},{"issue":"7","key":"b4","series-title":"PLoS One","first-page":"e22542","article-title":"Identification of RNF213 as a susceptibility gene for moyamoya disease and its possible role in vascular development","volume":"6","author":"Liu W","year":"2011","unstructured":"Liu W, Morito D, Takashima S,  Identification of RNF213 as a susceptibility gene for moyamoya disease and its possible role in vascular development. PLoS One. 2011; 6(7):e22542."},{"issue":"1","key":"b5","series-title":"Sci Rep","first-page":"3071","article-title":"Association of increased Treg and Th17 with pathogenesis of moyamoya disease","volume":"7","author":"Weng L","year":"2017","unstructured":"Weng L, Cao X, Han L,  Association of increased Treg and Th17 with pathogenesis of moyamoya disease. Sci Rep. 2017; 7(1):3071."},{"key":"b6","series-title":"Front Neurol","first-page":"1123951","article-title":"Clinical value of the systemic immune-inflammation index in moyamoya disease","volume":"14","author":"Liu E","year":"2023","unstructured":"Liu E, Liu C, Jin L,  Clinical value of the systemic immune-inflammation index in moyamoya disease. Front Neurol. 2023; 14:1123951."},{"issue":"11","key":"b7","series-title":"J Cereb Blood Flow Metab","first-page":"2107","article-title":"RNF213 loss of function reshapes vascular transcriptome and spliceosome leading to disrupted angiogenesis and aggravated vascular inflammatory responses","volume":"42","author":"Zhang L","year":"2022","unstructured":"Zhang L, Rashad S, Zhou Y, Niizuma K, Tominaga T. RNF213 loss of function reshapes vascular transcriptome and spliceosome leading to disrupted angiogenesis and aggravated vascular inflammatory responses. J Cereb Blood Flow Metab. 2022; 42(11):2107\u20132122."},{"key":"b8","series-title":"Front Endocrinol (Lausanne)","first-page":"1119227","article-title":"Acute-serum amyloid A and A-SAA-derived peptides as formyl peptide receptor (FPR) 2 ligands","volume":"14","author":"Abouelasrar Salama S","year":"2023","unstructured":"Abouelasrar Salama S, Gouwy M, Van Damme J, Struyf S. Acute-serum amyloid A and A-SAA-derived peptides as formyl peptide receptor (FPR) 2 ligands. Front Endocrinol (Lausanne). 2023; 14:1119227."},{"issue":"2","key":"b9","series-title":"FASEB J","first-page":"e23409","article-title":"FTO-mediated m6A modification of serum amyloid A2 mRNA promotes podocyte injury and inflammation by activating the NF-\u03baB signaling pathway","volume":"38","author":"Lang Y","year":"2024","unstructured":"Lang Y, Wang Q, Sheng Q,  FTO-mediated m6A modification of serum amyloid A2 mRNA promotes podocyte injury and inflammation by activating the NF-\u03baB signaling pathway. FASEB J. 2024; 38(2):e23409."},{"issue":"11","key":"b10","series-title":"PLoS One","first-page":"e13997","article-title":"Polymorphisms in the SAA1\/2 gene are associated with carotid intima media thickness in healthy Han Chinese subjects: the Cardiovascular Risk Survey","volume":"5","author":"Xie X","year":"2010","unstructured":"Xie X, Ma YT, Yang YN,  Polymorphisms in the SAA1\/2 gene are associated with carotid intima media thickness in healthy Han Chinese subjects: the Cardiovascular Risk Survey. PLoS One. 2010; 5(11):e13997."},{"issue":"1","key":"b11","series-title":"Scand J Immunol","first-page":"7","article-title":"Dexamethasone, but not IL-1 alone, upregulates acute-phase serum amyloid A gene expression and production by cultured human aortic smooth muscle cells","volume":"53","author":"Kumon Y","year":"2001","unstructured":"Kumon Y, Suehiro T, Hashimoto K, Sipe JD. Dexamethasone, but not IL-1 alone, upregulates acute-phase serum amyloid A gene expression and production by cultured human aortic smooth muscle cells. Scand J Immunol. 2001; 53(1):7\u201312."},{"issue":"5","key":"b12","series-title":"Neurol Med Chir (Tokyo)","first-page":"245","article-title":"Research Committee on the Pathology and Treatment of Spontaneous Occlusion of the Circle of Willis, Health Labour Sciences Research Grant on Measures for Infractable Diseases. Guidelines for diagnosis and treatment of moyamoya disease (spontaneous occlusion of the circle of Willis)","volume":"52","year":"2012","unstructured":"Research Committee on the Pathology and Treatment of Spontaneous Occlusion of the Circle of Willis, Health Labour Sciences Research Grant on Measures for Infractable Diseases. Guidelines for diagnosis and treatment of moyamoya disease (spontaneous occlusion of the circle of Willis). Neurol Med Chir (Tokyo). 2012; 52(5):245\u2013266."},{"issue":"12","key":"b13","series-title":"Stroke","first-page":"3153","article-title":"Upregulated cytoskeletal proteins promote pathological angiogenesis in moyamoya disease","volume":"54","author":"He S","year":"2023","unstructured":"He S, Zhang J, Liu Z,  Upregulated cytoskeletal proteins promote pathological angiogenesis in moyamoya disease. Stroke. 2023; 54(12):3153\u20133164."},{"issue":"16","key":"b14","series-title":"J Clin Med","first-page":"3628","article-title":"Clinical management of moyamoya patients","volume":"10","author":"Canavero I","year":"2021","unstructured":"Canavero I, Vetrano IG, Zedde M,  Clinical management of moyamoya patients. J Clin Med. 2021; 10(16):3628."},{"key":"b15","series-title":"Front Neurol","first-page":"608000","article-title":"Efficacy and safety of antiplatelet agents for adult patients with ischemic moyamoya disease","volume":"11","author":"Ye F","year":"2021","unstructured":"Ye F, Li J, Wang T,  Efficacy and safety of antiplatelet agents for adult patients with ischemic moyamoya disease. Front Neurol. 2021; 11:608000."},{"issue":"1","key":"b16","series-title":"Mol Med","first-page":"46","article-title":"Serum amyloid A\u2014a review","volume":"24","author":"Sack GH Jr","year":"2018","unstructured":"Sack GH Jr. Serum amyloid A\u2014a review. Mol Med. 2018; 24(1):46."},{"issue":"12","key":"b17","series-title":"Predominant localization to the epithelium. J Histochem Cytochem","first-page":"1377","article-title":"Widespread expression of serum amyloid A in histologically normal human tissues","volume":"46","author":"Urieli-Shoval S","year":"1998","unstructured":"Urieli-Shoval S, Cohen P, Eisenberg S, Matzner Y. Widespread expression of serum amyloid A in histologically normal human tissues. Predominant localization to the epithelium. J Histochem Cytochem. 1998; 46(12):1377\u20131384."},{"issue":"12","key":"b18","series-title":"Biomolecules","first-page":"1883","article-title":"Role of serum amyloid A in abdominal aortic aneurysm and related cardiovascular diseases","volume":"11","author":"Shridas P","year":"2021","unstructured":"Shridas P, Patrick AC, Tannock LR. Role of serum amyloid A in abdominal aortic aneurysm and related cardiovascular diseases. Biomolecules. 2021; 11(12):1883."},{"issue":"1115","key":"b19","series-title":"Postgrad Med J","first-page":"499","article-title":"Association between serum amyloid A levels and cancers: a systematic review and meta-analysis","volume":"94","author":"Zhou J","year":"2018","unstructured":"Zhou J, Sheng J, Fan Y,  Association between serum amyloid A levels and cancers: a systematic review and meta-analysis. Postgrad Med J. 2018; 94(1115):499\u2013507."},{"issue":"7","key":"b20","series-title":"J Am Heart Assoc","first-page":"e001858","article-title":"Serum amyloid A facilitates early lesion development in Ldlr\u2212\/\u2212 mice","volume":"4","author":"Krishack PA","year":"2015","unstructured":"Krishack PA, Bhanvadia CV, Lukens J,  Serum amyloid A facilitates early lesion development in Ldlr\u2212\/\u2212 mice. J Am Heart Assoc. 2015; 4(7):e001858."},{"issue":"5","key":"b21","series-title":"Redox Rep","first-page":"187","article-title":"A role for acute-phase serum amyloid A and high-density lipoprotein in oxidative stress, endothelial dysfunction and atherosclerosis","volume":"14","author":"Hua S","year":"2009","unstructured":"Hua S, Song C, Geczy CL, Freedman SB, Witting PK. A role for acute-phase serum amyloid A and high-density lipoprotein in oxidative stress, endothelial dysfunction and atherosclerosis. Redox Rep. 2009; 14(5):187\u2013196."},{"issue":"5","key":"b22","series-title":"Arterioscler Thromb Vasc Biol","first-page":"632","article-title":"Adipocyte-derived serum amyloid A promotes angiotensin II-induced abdominal aortic aneurysms in obese C57BL\/6J mice","volume":"42","author":"Shridas P","year":"2022","unstructured":"Shridas P, Ji A, Trumbauer AC,  Adipocyte-derived serum amyloid A promotes angiotensin II-induced abdominal aortic aneurysms in obese C57BL\/6J mice. Arterioscler Thromb Vasc Biol. 2022; 42(5):632\u2013643."},{"issue":"4","key":"b23","series-title":"Amyloid","first-page":"237","article-title":"Acute-phase, but not constitutive serum amyloid A (SAA) is chemotactic for cultured human aortic smooth muscle cells","volume":"9","author":"Kumon Y","year":"2003","unstructured":"Kumon Y, Hosokawa T, Suehiro T, Ikeda Y, Sipe JD, Hashimoto K. Acute-phase, but not constitutive serum amyloid A (SAA) is chemotactic for cultured human aortic smooth muscle cells. Amyloid. 2003; 9(4):237\u2013241."},{"issue":"9","key":"b24","series-title":"Clin Exp Pharmacol Physiol","first-page":"662","article-title":"Serum amyloid A stimulates cultured endothelial cells to migrate and proliferate: inhibition by the multikinase inhibitor BIBF1120","volume":"40","author":"Cai X","year":"2013","unstructured":"Cai X, Freedman SB, Witting PK. Serum amyloid A stimulates cultured endothelial cells to migrate and proliferate: inhibition by the multikinase inhibitor BIBF1120. Clin Exp Pharmacol Physiol. 2013; 40(9):662\u2013670."},{"issue":"1","key":"b25","series-title":"J Physiol Biochem","first-page":"71","article-title":"Serum amyloid A stimulates vascular endothelial growth factor receptor 2 expression and angiogenesis","volume":"72","author":"Lv M","year":"2016","unstructured":"Lv M, Xia YF, Li B,  Serum amyloid A stimulates vascular endothelial growth factor receptor 2 expression and angiogenesis. J Physiol Biochem. 2016; 72(1):71\u201381."},{"issue":"3","key":"b26","series-title":"Neuropathology","first-page":"236","article-title":"Pathological and immunohistochemical findings of an autopsy case of adult moyamoya disease","volume":"24","author":"Takekawa Y","year":"2004","unstructured":"Takekawa Y, Umezawa T, Ueno Y, Sawada T, Kobayashi M. Pathological and immunohistochemical findings of an autopsy case of adult moyamoya disease. Neuropathology. 2004; 24(3):236\u2013242."},{"issue":"1","key":"b27","series-title":"Neurol Med Chir (Tokyo)","first-page":"1","article-title":"Histological features of middle cerebral arteries from patients treated for Moyamoya disease","volume":"47","author":"Takagi Y","year":"2007","unstructured":"Takagi Y, Kikuta K, Nozaki K, Hashimoto N. Histological features of middle cerebral arteries from patients treated for Moyamoya disease. Neurol Med Chir (Tokyo). 2007; 47(1):1\u20134."},{"key":"b28","series-title":"Front Neurol","first-page":"661578","article-title":"Pathophysiology of vascular stenosis and remodeling in moyamoya disease","volume":"12","author":"Fox BM","year":"2021","unstructured":"Fox BM, Dorschel KB, Lawton MT, Wanebo JE. Pathophysiology of vascular stenosis and remodeling in moyamoya disease. Front Neurol. 2021; 12:661578."},{"issue":"9","key":"b29","series-title":"Arterioscler Thromb Vasc Biol","first-page":"1715","article-title":"Smooth muscle cell phenotypic diversity","volume":"39","author":"Liu M","year":"2019","unstructured":"Liu M, Gomez D. Smooth muscle cell phenotypic diversity. Arterioscler Thromb Vasc Biol. 2019; 39(9):1715\u20131723."},{"key":"b30","series-title":"Cell Signal","first-page":"48","article-title":"Smooth muscle cell-driven vascular diseases and molecular mechanisms of VSMC plasticity","volume":"52","author":"Frismantiene A","year":"2018","unstructured":"Frismantiene A, Philippova M, Erne P, Resink TJ. Smooth muscle cell-driven vascular diseases and molecular mechanisms of VSMC plasticity. Cell Signal. 2018; 52:48\u201364."},{"issue":"3","key":"b31","series-title":"Physiol Rev","first-page":"767","article-title":"Molecular regulation of vascular smooth muscle cell differentiation in development and disease","volume":"84","author":"Owens GK","year":"2004","unstructured":"Owens GK, Kumar MS, Wamhoff BR. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev. 2004; 84(3):767\u2013801."},{"issue":"12","key":"b32","series-title":"Nat Rev Cardiol","first-page":"727","article-title":"Vascular smooth muscle cells in atherosclerosis","volume":"16","author":"Basatemur GL","year":"2019","unstructured":"Basatemur GL, J\u00f8rgensen HF, Clarke MCH, Bennett MR, Mallat Z. Vascular smooth muscle cells in atherosclerosis. Nat Rev Cardiol. 2019; 16(12):727\u2013744."},{"issue":"6","key":"b33","series-title":"Stroke","first-page":"1490","article-title":"Clinical features and outcome in North American adults with moyamoya phenomenon","volume":"37","author":"Hallemeier CL","year":"2006","unstructured":"Hallemeier CL, Rich KM, Grubb RL Jr,  Clinical features and outcome in North American adults with moyamoya phenomenon. Stroke. 2006; 37(6):1490\u20131496."},{"issue":"12","key":"b34","series-title":"Stroke","first-page":"3193","article-title":"Moyamoya disease in Europeans","volume":"39","author":"Kraemer M","year":"2008","unstructured":"Kraemer M, Heienbrok W, Berlit P. Moyamoya disease in Europeans. Stroke. 2008; 39(12):3193\u20133200."},{"issue":"6","key":"b35","series-title":"J Neurol Neurosurg Psychiatry","first-page":"673","article-title":"Plasma matrix metalloproteinases, cytokines and angiogenic factors in moyamoya disease","volume":"81","author":"Kang HS","year":"2010","unstructured":"Kang HS, Kim JH, Phi JH,  Plasma matrix metalloproteinases, cytokines and angiogenic factors in moyamoya disease. J Neurol Neurosurg Psychiatry. 2010; 81(6):673\u2013678."},{"issue":"4","key":"b36","series-title":"PLoS One","first-page":"e36386","article-title":"Clinical and immunopathological features of Moyamoya disease","volume":"7","author":"Lin R","year":"2012","unstructured":"Lin R, Xie Z, Zhang J,  Clinical and immunopathological features of Moyamoya disease. PLoS One. 2012; 7(4):e36386."},{"issue":"11","key":"b37","series-title":"Trends Mol Med","first-page":"939","article-title":"Moyamoya disease emerging as an immune-related angiopathy","volume":"28","author":"Asselman C","year":"2022","unstructured":"Asselman C, Hemelsoet D, Eggermont D, Dermaut B, Impens F. Moyamoya disease emerging as an immune-related angiopathy. Trends Mol Med. 2022; 28(11):939\u2013950."},{"issue":"3","key":"b38","series-title":"Neurol Genet","first-page":"e592","article-title":"Association of HLA-DQA2 and HLA-B with moyamoya disease in the Chinese Han population","volume":"7","author":"Wan J","year":"2021","unstructured":"Wan J, Ling W, Zhengshan Z, Xianbo Z, Lian D, Kai W. Association of HLA-DQA2 and HLA-B with moyamoya disease in the Chinese Han population. Neurol Genet. 2021; 7(3):e592."},{"issue":"10","key":"b39","series-title":"Stroke","first-page":"e465","article-title":"Adult moyamoya disease and syndrome: current perspectives and future directions: a scientific statement from the American Heart Association\/American Stroke Association","volume":"54","author":"Gonzalez NR","year":"2023","unstructured":"Gonzalez NR, Amin-Hanjani S, Bang OY,  Adult moyamoya disease and syndrome: current perspectives and future directions: a scientific statement from the American Heart Association\/American Stroke Association. Stroke. 2023; 54(10):e465\u2013e479."},{"issue":"1","key":"b40","series-title":"Sci Rep","first-page":"19367","article-title":"Benefits and risks of antiplatelet medication in hemodynamically stable adult moyamoya disease","volume":"11","author":"Pang CH","year":"2021","unstructured":"Pang CH, Cho WS, Kang HS, Kim JE. Benefits and risks of antiplatelet medication in hemodynamically stable adult moyamoya disease. Sci Rep. 2021; 11(1):19367."},{"issue":"11","key":"b1","series-title":"Lancet Neurol","first-page":"1056","article-title":"Moyamoya disease: current concepts and future perspectives","volume":"7","author":"Kuroda S","year":"2008","unstructured":"Kuroda S, Houkin K. Moyamoya disease: current concepts and future perspectives. Lancet Neurol. 2008; 7(11):1056\u20131066."},{"issue":"7","key":"b2","series-title":"Stroke","first-page":"e364","article-title":"2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: a guideline from the American Heart Association\/American Stroke Association","volume":"52","author":"Kleindorfer DO","year":"2021","unstructured":"Kleindorfer DO, Towfighi A, Chaturvedi S,  2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: a guideline from the American Heart Association\/American Stroke Association. Stroke. 2021; 52(7):e364\u2013e467."},{"key":"b3","series-title":"Front Pharmacol","first-page":"841174","article-title":"Effects of aspirin therapy on bypass efficacy and survival of patients receiving direct cerebral revascularization","volume":"13","author":"Xiang Y","year":"2022","unstructured":"Xiang Y, Zhang P, Zhao P,  Effects of aspirin therapy on bypass efficacy and survival of patients receiving direct cerebral revascularization. Front Pharmacol. 2022; 13:841174."},{"issue":"7","key":"b4","series-title":"PLoS One","first-page":"e22542","article-title":"Identification of RNF213 as a susceptibility gene for moyamoya disease and its possible role in vascular development","volume":"6","author":"Liu W","year":"2011","unstructured":"Liu W, Morito D, Takashima S,  Identification of RNF213 as a susceptibility gene for moyamoya disease and its possible role in vascular development. PLoS One. 2011; 6(7):e22542."},{"issue":"1","key":"b5","series-title":"Sci Rep","first-page":"3071","article-title":"Association of increased Treg and Th17 with pathogenesis of moyamoya disease","volume":"7","author":"Weng L","year":"2017","unstructured":"Weng L, Cao X, Han L,  Association of increased Treg and Th17 with pathogenesis of moyamoya disease. Sci Rep. 2017; 7(1):3071."},{"key":"b6","series-title":"Front Neurol","first-page":"1123951","article-title":"Clinical value of the systemic immune-inflammation index in moyamoya disease","volume":"14","author":"Liu E","year":"2023","unstructured":"Liu E, Liu C, Jin L,  Clinical value of the systemic immune-inflammation index in moyamoya disease. Front Neurol. 2023; 14:1123951."},{"issue":"11","key":"b7","series-title":"J Cereb Blood Flow Metab","first-page":"2107","article-title":"RNF213 loss of function reshapes vascular transcriptome and spliceosome leading to disrupted angiogenesis and aggravated vascular inflammatory responses","volume":"42","author":"Zhang L","year":"2022","unstructured":"Zhang L, Rashad S, Zhou Y, Niizuma K, Tominaga T. RNF213 loss of function reshapes vascular transcriptome and spliceosome leading to disrupted angiogenesis and aggravated vascular inflammatory responses. J Cereb Blood Flow Metab. 2022; 42(11):2107\u20132122."},{"key":"b8","series-title":"Front Endocrinol (Lausanne)","first-page":"1119227","article-title":"Acute-serum amyloid A and A-SAA-derived peptides as formyl peptide receptor (FPR) 2 ligands","volume":"14","author":"Abouelasrar Salama S","year":"2023","unstructured":"Abouelasrar Salama S, Gouwy M, Van Damme J, Struyf S. Acute-serum amyloid A and A-SAA-derived peptides as formyl peptide receptor (FPR) 2 ligands. Front Endocrinol (Lausanne). 2023; 14:1119227."},{"issue":"2","key":"b9","series-title":"FASEB J","first-page":"e23409","article-title":"FTO-mediated m6A modification of serum amyloid A2 mRNA promotes podocyte injury and inflammation by activating the NF-\u03baB signaling pathway","volume":"38","author":"Lang Y","year":"2024","unstructured":"Lang Y, Wang Q, Sheng Q,  FTO-mediated m6A modification of serum amyloid A2 mRNA promotes podocyte injury and inflammation by activating the NF-\u03baB signaling pathway. FASEB J. 2024; 38(2):e23409."},{"issue":"11","key":"b10","series-title":"PLoS One","first-page":"e13997","article-title":"Polymorphisms in the SAA1\/2 gene are associated with carotid intima media thickness in healthy Han Chinese subjects: the Cardiovascular Risk Survey","volume":"5","author":"Xie X","year":"2010","unstructured":"Xie X, Ma YT, Yang YN,  Polymorphisms in the SAA1\/2 gene are associated with carotid intima media thickness in healthy Han Chinese subjects: the Cardiovascular Risk Survey. PLoS One. 2010; 5(11):e13997."},{"issue":"1","key":"b11","series-title":"Scand J Immunol","first-page":"7","article-title":"Dexamethasone, but not IL-1 alone, upregulates acute-phase serum amyloid A gene expression and production by cultured human aortic smooth muscle cells","volume":"53","author":"Kumon Y","year":"2001","unstructured":"Kumon Y, Suehiro T, Hashimoto K, Sipe JD. Dexamethasone, but not IL-1 alone, upregulates acute-phase serum amyloid A gene expression and production by cultured human aortic smooth muscle cells. Scand J Immunol. 2001; 53(1):7\u201312."},{"issue":"5","key":"b12","series-title":"Neurol Med Chir (Tokyo)","first-page":"245","article-title":"Research Committee on the Pathology and Treatment of Spontaneous Occlusion of the Circle of Willis, Health Labour Sciences Research Grant on Measures for Infractable Diseases. Guidelines for diagnosis and treatment of moyamoya disease (spontaneous occlusion of the circle of Willis)","volume":"52","year":"2012","unstructured":"Research Committee on the Pathology and Treatment of Spontaneous Occlusion of the Circle of Willis, Health Labour Sciences Research Grant on Measures for Infractable Diseases. Guidelines for diagnosis and treatment of moyamoya disease (spontaneous occlusion of the circle of Willis). Neurol Med Chir (Tokyo). 2012; 52(5):245\u2013266."},{"issue":"12","key":"b13","series-title":"Stroke","first-page":"3153","article-title":"Upregulated cytoskeletal proteins promote pathological angiogenesis in moyamoya disease","volume":"54","author":"He S","year":"2023","unstructured":"He S, Zhang J, Liu Z,  Upregulated cytoskeletal proteins promote pathological angiogenesis in moyamoya disease. Stroke. 2023; 54(12):3153\u20133164."},{"issue":"16","key":"b14","series-title":"J Clin Med","first-page":"3628","article-title":"Clinical management of moyamoya patients","volume":"10","author":"Canavero I","year":"2021","unstructured":"Canavero I, Vetrano IG, Zedde M,  Clinical management of moyamoya patients. J Clin Med. 2021; 10(16):3628."},{"key":"b15","series-title":"Front Neurol","first-page":"608000","article-title":"Efficacy and safety of antiplatelet agents for adult patients with ischemic moyamoya disease","volume":"11","author":"Ye F","year":"2021","unstructured":"Ye F, Li J, Wang T,  Efficacy and safety of antiplatelet agents for adult patients with ischemic moyamoya disease. Front Neurol. 2021; 11:608000."},{"issue":"1","key":"b16","series-title":"Mol Med","first-page":"46","article-title":"Serum amyloid A\u2014a review","volume":"24","author":"Sack GH Jr","year":"2018","unstructured":"Sack GH Jr. Serum amyloid A\u2014a review. Mol Med. 2018; 24(1):46."},{"issue":"12","key":"b17","series-title":"Predominant localization to the epithelium. J Histochem Cytochem","first-page":"1377","article-title":"Widespread expression of serum amyloid A in histologically normal human tissues","volume":"46","author":"Urieli-Shoval S","year":"1998","unstructured":"Urieli-Shoval S, Cohen P, Eisenberg S, Matzner Y. Widespread expression of serum amyloid A in histologically normal human tissues. Predominant localization to the epithelium. J Histochem Cytochem. 1998; 46(12):1377\u20131384."},{"issue":"12","key":"b18","series-title":"Biomolecules","first-page":"1883","article-title":"Role of serum amyloid A in abdominal aortic aneurysm and related cardiovascular diseases","volume":"11","author":"Shridas P","year":"2021","unstructured":"Shridas P, Patrick AC, Tannock LR. Role of serum amyloid A in abdominal aortic aneurysm and related cardiovascular diseases. Biomolecules. 2021; 11(12):1883."},{"issue":"1115","key":"b19","series-title":"Postgrad Med J","first-page":"499","article-title":"Association between serum amyloid A levels and cancers: a systematic review and meta-analysis","volume":"94","author":"Zhou J","year":"2018","unstructured":"Zhou J, Sheng J, Fan Y,  Association between serum amyloid A levels and cancers: a systematic review and meta-analysis. Postgrad Med J. 2018; 94(1115):499\u2013507."},{"issue":"7","key":"b20","series-title":"J Am Heart Assoc","first-page":"e001858","article-title":"Serum amyloid A facilitates early lesion development in Ldlr\u2212\/\u2212 mice","volume":"4","author":"Krishack PA","year":"2015","unstructured":"Krishack PA, Bhanvadia CV, Lukens J,  Serum amyloid A facilitates early lesion development in Ldlr\u2212\/\u2212 mice. J Am Heart Assoc. 2015; 4(7):e001858."},{"issue":"5","key":"b21","series-title":"Redox Rep","first-page":"187","article-title":"A role for acute-phase serum amyloid A and high-density lipoprotein in oxidative stress, endothelial dysfunction and atherosclerosis","volume":"14","author":"Hua S","year":"2009","unstructured":"Hua S, Song C, Geczy CL, Freedman SB, Witting PK. A role for acute-phase serum amyloid A and high-density lipoprotein in oxidative stress, endothelial dysfunction and atherosclerosis. Redox Rep. 2009; 14(5):187\u2013196."},{"issue":"5","key":"b22","series-title":"Arterioscler Thromb Vasc Biol","first-page":"632","article-title":"Adipocyte-derived serum amyloid A promotes angiotensin II-induced abdominal aortic aneurysms in obese C57BL\/6J mice","volume":"42","author":"Shridas P","year":"2022","unstructured":"Shridas P, Ji A, Trumbauer AC,  Adipocyte-derived serum amyloid A promotes angiotensin II-induced abdominal aortic aneurysms in obese C57BL\/6J mice. Arterioscler Thromb Vasc Biol. 2022; 42(5):632\u2013643."},{"issue":"4","key":"b23","series-title":"Amyloid","first-page":"237","article-title":"Acute-phase, but not constitutive serum amyloid A (SAA) is chemotactic for cultured human aortic smooth muscle cells","volume":"9","author":"Kumon Y","year":"2003","unstructured":"Kumon Y, Hosokawa T, Suehiro T, Ikeda Y, Sipe JD, Hashimoto K. Acute-phase, but not constitutive serum amyloid A (SAA) is chemotactic for cultured human aortic smooth muscle cells. Amyloid. 2003; 9(4):237\u2013241."},{"issue":"9","key":"b24","series-title":"Clin Exp Pharmacol Physiol","first-page":"662","article-title":"Serum amyloid A stimulates cultured endothelial cells to migrate and proliferate: inhibition by the multikinase inhibitor BIBF1120","volume":"40","author":"Cai X","year":"2013","unstructured":"Cai X, Freedman SB, Witting PK. Serum amyloid A stimulates cultured endothelial cells to migrate and proliferate: inhibition by the multikinase inhibitor BIBF1120. Clin Exp Pharmacol Physiol. 2013; 40(9):662\u2013670."},{"issue":"1","key":"b25","series-title":"J Physiol Biochem","first-page":"71","article-title":"Serum amyloid A stimulates vascular endothelial growth factor receptor 2 expression and angiogenesis","volume":"72","author":"Lv M","year":"2016","unstructured":"Lv M, Xia YF, Li B,  Serum amyloid A stimulates vascular endothelial growth factor receptor 2 expression and angiogenesis. J Physiol Biochem. 2016; 72(1):71\u201381."},{"issue":"3","key":"b26","series-title":"Neuropathology","first-page":"236","article-title":"Pathological and immunohistochemical findings of an autopsy case of adult moyamoya disease","volume":"24","author":"Takekawa Y","year":"2004","unstructured":"Takekawa Y, Umezawa T, Ueno Y, Sawada T, Kobayashi M. Pathological and immunohistochemical findings of an autopsy case of adult moyamoya disease. Neuropathology. 2004; 24(3):236\u2013242."},{"issue":"1","key":"b27","series-title":"Neurol Med Chir (Tokyo)","first-page":"1","article-title":"Histological features of middle cerebral arteries from patients treated for Moyamoya disease","volume":"47","author":"Takagi Y","year":"2007","unstructured":"Takagi Y, Kikuta K, Nozaki K, Hashimoto N. Histological features of middle cerebral arteries from patients treated for Moyamoya disease. Neurol Med Chir (Tokyo). 2007; 47(1):1\u20134."},{"key":"b28","series-title":"Front Neurol","first-page":"661578","article-title":"Pathophysiology of vascular stenosis and remodeling in moyamoya disease","volume":"12","author":"Fox BM","year":"2021","unstructured":"Fox BM, Dorschel KB, Lawton MT, Wanebo JE. Pathophysiology of vascular stenosis and remodeling in moyamoya disease. Front Neurol. 2021; 12:661578."},{"issue":"9","key":"b29","series-title":"Arterioscler Thromb Vasc Biol","first-page":"1715","article-title":"Smooth muscle cell phenotypic diversity","volume":"39","author":"Liu M","year":"2019","unstructured":"Liu M, Gomez D. Smooth muscle cell phenotypic diversity. Arterioscler Thromb Vasc Biol. 2019; 39(9):1715\u20131723."},{"key":"b30","series-title":"Cell Signal","first-page":"48","article-title":"Smooth muscle cell-driven vascular diseases and molecular mechanisms of VSMC plasticity","volume":"52","author":"Frismantiene A","year":"2018","unstructured":"Frismantiene A, Philippova M, Erne P, Resink TJ. Smooth muscle cell-driven vascular diseases and molecular mechanisms of VSMC plasticity. Cell Signal. 2018; 52:48\u201364."},{"issue":"3","key":"b31","series-title":"Physiol Rev","first-page":"767","article-title":"Molecular regulation of vascular smooth muscle cell differentiation in development and disease","volume":"84","author":"Owens GK","year":"2004","unstructured":"Owens GK, Kumar MS, Wamhoff BR. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev. 2004; 84(3):767\u2013801."},{"issue":"12","key":"b32","series-title":"Nat Rev Cardiol","first-page":"727","article-title":"Vascular smooth muscle cells in atherosclerosis","volume":"16","author":"Basatemur GL","year":"2019","unstructured":"Basatemur GL, J\u00f8rgensen HF, Clarke MCH, Bennett MR, Mallat Z. Vascular smooth muscle cells in atherosclerosis. Nat Rev Cardiol. 2019; 16(12):727\u2013744."},{"issue":"6","key":"b33","series-title":"Stroke","first-page":"1490","article-title":"Clinical features and outcome in North American adults with moyamoya phenomenon","volume":"37","author":"Hallemeier CL","year":"2006","unstructured":"Hallemeier CL, Rich KM, Grubb RL Jr,  Clinical features and outcome in North American adults with moyamoya phenomenon. Stroke. 2006; 37(6):1490\u20131496."},{"issue":"12","key":"b34","series-title":"Stroke","first-page":"3193","article-title":"Moyamoya disease in Europeans","volume":"39","author":"Kraemer M","year":"2008","unstructured":"Kraemer M, Heienbrok W, Berlit P. Moyamoya disease in Europeans. Stroke. 2008; 39(12):3193\u20133200."},{"issue":"6","key":"b35","series-title":"J Neurol Neurosurg Psychiatry","first-page":"673","article-title":"Plasma matrix metalloproteinases, cytokines and angiogenic factors in moyamoya disease","volume":"81","author":"Kang HS","year":"2010","unstructured":"Kang HS, Kim JH, Phi JH,  Plasma matrix metalloproteinases, cytokines and angiogenic factors in moyamoya disease. J Neurol Neurosurg Psychiatry. 2010; 81(6):673\u2013678."},{"issue":"4","key":"b36","series-title":"PLoS One","first-page":"e36386","article-title":"Clinical and immunopathological features of Moyamoya disease","volume":"7","author":"Lin R","year":"2012","unstructured":"Lin R, Xie Z, Zhang J,  Clinical and immunopathological features of Moyamoya disease. PLoS One. 2012; 7(4):e36386."},{"issue":"11","key":"b37","series-title":"Trends Mol Med","first-page":"939","article-title":"Moyamoya disease emerging as an immune-related angiopathy","volume":"28","author":"Asselman C","year":"2022","unstructured":"Asselman C, Hemelsoet D, Eggermont D, Dermaut B, Impens F. Moyamoya disease emerging as an immune-related angiopathy. Trends Mol Med. 2022; 28(11):939\u2013950."},{"issue":"3","key":"b38","series-title":"Neurol Genet","first-page":"e592","article-title":"Association of HLA-DQA2 and HLA-B with moyamoya disease in the Chinese Han population","volume":"7","author":"Wan J","year":"2021","unstructured":"Wan J, Ling W, Zhengshan Z, Xianbo Z, Lian D, Kai W. Association of HLA-DQA2 and HLA-B with moyamoya disease in the Chinese Han population. Neurol Genet. 2021; 7(3):e592."},{"issue":"10","key":"b39","series-title":"Stroke","first-page":"e465","article-title":"Adult moyamoya disease and syndrome: current perspectives and future directions: a scientific statement from the American Heart Association\/American Stroke Association","volume":"54","author":"Gonzalez NR","year":"2023","unstructured":"Gonzalez NR, Amin-Hanjani S, Bang OY,  Adult moyamoya disease and syndrome: current perspectives and future directions: a scientific statement from the American Heart Association\/American Stroke Association. Stroke. 2023; 54(10):e465\u2013e479."},{"issue":"1","key":"b40","series-title":"Sci Rep","first-page":"19367","article-title":"Benefits and risks of antiplatelet medication in hemodynamically stable adult moyamoya disease","volume":"11","author":"Pang CH","year":"2021","unstructured":"Pang CH, Cho WS, Kang HS, Kim JE. Benefits and risks of antiplatelet medication in hemodynamically stable adult moyamoya disease. Sci Rep. 2021; 11(1):19367."}],"container-title":["Journal of Neurosurgery"],"original-title":[],"link":[{"URL":"https:\/\/thejns.org\/view\/journals\/j-neurosurg\/143\/2\/article-p530.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/thejns.org\/downloadpdf\/journals\/j-neurosurg\/143\/2\/article-p530.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/thejns.org\/downloadpdf\/journals\/j-neurosurg\/143\/2\/article-p530.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T14:28:41Z","timestamp":1772720921000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejns.org\/view\/journals\/j-neurosurg\/143\/2\/article-p530.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":80,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.3171\/2024.11.jns241804","relation":{},"ISSN":["0022-3085","1933-0693"],"issn-type":[{"value":"0022-3085","type":"print"},{"value":"1933-0693","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,1]]}}}